Expression and Clinical Significance of Tumor Markers CEA and CYFRA21-1 in Patients with Lung Cancer

Abstract

To explore the application value of tumor markers carcinoembryonic antigen and cytokeratin 19 fragment in the progression and prognosis of middle-advanced non-small cell lung cancer. Clinical data of 97 patients initially diagnosed with lung lesions in our hospital from January 2018 to December 2019 were collected and divided into the lung cancer group and benign lesion group. There were 52 patients diagnosed with stage I or II lung cancer by computed tomography and clinical diagnosis in the lung cancer group and 45 patients with benign lesions in the benign lesion group. The levels of serum tumor markers were detected by electrochemiluminescence immunoassay. The results showed that the levels of carcinoembryonic antigen and cytokeratin 19 were significantly higher in the lung cancer group compared with the benign lesion group and the difference was statistically significant (p<0.05). Both carcinoembryonic antigen and cytokeratin 19 can be used in the diagnosis of squamous cell carcinoma and adenocarcinoma. The sensitivity of the combined detection was significantly higher than that of the single detection, while the specificity of the combined detection was significantly lower than that of carcinoembryonic antigen alone (p<0.05). In lung cancer with positive combined detection, the proportion of adenocarcinoma was significantly higher than that of squamous cell carcinoma. When cytokeratin 19 was positive and carcinoembryonic antigen was negative, the proportion of squamous cell carcinoma was significantly higher than that of adenocarcinoma. Serum carcinoembryonic antigen and cytokeratin 19 were abnormally highly expressed in non-Small cell lung cancer patients, which are useful for clinical diagnosing, treatment planning, efficacy monitoring, and prognosis evaluation.

LncRNA-MALAT1: A Key Participant in the Occurrence and Development of Cancer

“…For patients with lung cancer, the expression characteristics of lncRNA-MALAT1 in serum can be used as a marker for diagnosis [62], whereas the expression level of lncRNA-MALAT1 has some value in the identification of the pathological types of lung cancer. In addition, the combination of lncRNAs in plasma with classical tumor markers, CEA or Cyfra21-1, can enhance the diagnostic efficacy of lncRNAs in patients with lung cancer [63]. This can be further studied or combined with other markers to improve the accuracy of a lung cancer diagnosis.…”